Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Breast cancer research and treatment 16 (1990), S. 15-22 
    ISSN: 1573-7217
    Keywords: inflammatory breast cancer ; prognostic classes ; initial chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Prognostic factors were identified in a group of 210 patients with inflammatory breast carcinoma (IBC) treated at Institut Gustave Roussy from 1976–1985 with three successive induction protocols: Group A (n = 91), 1976–1980, doxorubicin, vincristine, methotrexate (AVM); Group B (n = 79), 1980–1982, doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (AVCMF); Group C (n = 40), 1983–1985, AVCMF. Groups A and B received 3 courses of respective chemotherapy (Ct) followed by radiotherapy (Rt), 45 Gy to breast and nodes and 65–70 Gy to the tumor. Group C after the third Ct course received split courses of Rt to equivalent doses so there was no time lag between Ct courses. Ct from fourth to ninth courses was AVM in all groups. Hormonal therapy, radiocastration (pre and perimenopausal) or tamoxifen (postmenopausal) was given all patients. Clinical characteristics of age, menopausal status, castration, N status, and degree of clinical inflammation (limited to tumor area [PEV 2] or involving the entire breast [PEV 3]) were similar in all groups. Groups B and C had identical disease-free and overall survivals, superior to Group A (p = 0.005). In multi-variate analysis, AVCMF was one of the important prognostic factors together with PEV and N status. Three prognostic classes were identified: I (n = 66) — PEV 2 and N0-1 (relative risk (RR) of relapse 0.80X) where AVM was as effective as AVCMF; II (n = 126) — either N2-3 or PEV 3 (RR 1.10X) where AVCMF was statistically superior to AVM and reduced the RR significantly (p = 0.02); III (n = 18) — PEV 3 and N2-3 (RR 1.9X) where Ct increased neither DFS nor OS over a historical Rt-only group. For class III a much more aggressive Ct such as initial myeloablative therapy with bone marrow autograft may be useful, which may also further improve survival in chemosensitive class II.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Breast cancer research and treatment 11 (1988), S. 273-276 
    ISSN: 1573-7217
    Keywords: breast cancer ; CA 15.3 ; CEA ; circulating antigens ; sensitivity ; serum markers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract 211 patients with various stages of breast cancer were studied by both the CA 15.3 and CEA markers to assess whether the latter may increase the screening sensitivity of the former. While both markers were equally specific, CA 15.3 was seen to be much more sensitive than CEA (p〈0.0001). Also, the addition of the CEA did not add appreciably (7%) to positive detection by CA 15.3. There appears to be no advantage to including CEA in a marker panel to follow the course of breast carcinoma.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...